• Dosage of Liskobutol in details
• Liskobutol interactions
• Liskobutol reviews

Dosage of Liskobutol in details

Liskobutol Dosage

Applies to the following strength(s): 100 mg; 400 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

• Tuberculosis - Active
• Mycobacterium avium-intracellulare - Treatment
• Mycobacterium avium-intracellulare - Prophylaxis

Usual Pediatric Dose for:

• Tuberculosis - Active
• Mycobacterium avium-intracellulare - Treatment
• Mycobacterium avium-intracellulare - Prophylaxis

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Tuberculosis - Active

Initial treatment: 15 mg/kg orally once a day for 6 to 8 weeks with concurrent isoniazid therapy.

Retreatment: 25 mg/kg orally once a day for 60 days concurrently with at least one other anti-TB drug. After 60 days, decrease dose to 15 mg/kg orally once a day.

As an alternative to single daily dose, a dose of 40 mg/kg orally twice a week or 30 mg/kg orally 3 times a week can be administered. This generally follows 2 weeks of daily therapy. This regimen allows directly observed therapy (DOT).

Usual Adult Dose for Mycobacterium avium-intracellulare - Treatment

900 mg orally once a day. Pulmonary AVI treatment consists of clarithromycin and 2 to 4 other drugs such as Liskobutol, rifampin, clofazimine, and/or other agents. The duration of treatment is 18 to 24 months.

Disseminated MAI treatment consists of clarithromycin or azithromycin and 1 to 3 other drugs such as Liskobutol, clofazamine, ciprofloxacin, ofloxacin, rifampin, rifabutin, or amikacin. As long as clinical and microbiological response is documented, therapy should be continued for life.

Usual Adult Dose for Mycobacterium avium-intracellulare - Prophylaxis

15 mg/kg orally once a day. Used in combination therapy with clarithromycin or azithromycin. Therapy should be continued for life.

Usual Pediatric Dose for Tuberculosis - Active

Greater than 13 years:

Initial treatment: 15 mg/kg orally once a day for 6 to 8 weeks with concurrent isoniazid therapy.

Retreatment: 25 mg/kg orally once a day for 60 days concurrently with at least one other anti-TB drug. After 60 days, decrease dose to 15 mg/kg orally once a day.

As an alternative to single daily dose, a dose of 40 mg/kg orally twice a week or 30 mg/kg orally 3 times a week can be administered. This generally follows 2 weeks of daily therapy. This regimen allows directly observed therapy (DOT).

Usual Pediatric Dose for Mycobacterium avium-intracellulare - Treatment

Greater than 13 years:

900 mg orally once a day. Pulmonary AVI treatment consists of clarithromycin and 2 to 4 other drugs such as Liskobutol, rifampin, clofazimine, and/or other agents. The duration of treatment is 18 to 24 months.

Disseminated MAI treatment consists of clarithromycin or azithromycin and 1 to 3 other drugs such as Liskobutol, clofazamine, ciprofloxacin, ofloxacin, rifampin, rifabutin, or amikacin. As long as clinical and microbiological response is documented, therapy should be continued for life.

Usual Pediatric Dose for Mycobacterium avium-intracellulare - Prophylaxis

Greater than 13 years:

15 mg/kg orally once a day. Used in combination therapy with clarithromycin or azithromycin. Therapy should be continued for life.

Renal Dose Adjustments

CrCl less than 10 mL/min: The usual dose may be administered every 48 hours.

CrCl 10 to 50 mL/min: The usual dose may be administered every 24 to 36 hours.

Liver Dose Adjustments

Data not available

Dose Adjustments

Patients with decreased renal function need the dosage reduced as determined by serum levels, since the main path of excretion of this drug is by the kidneys.

Precautions

Liskobutol is contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be administered. Liskobutol is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

Due to the risk of optic neuritis associated with Liskobutol, caution should be used when treating patients with preexisting neuritis or other vision defects. Liskobutol may produce decreases in visual acuity that appear to be due to optic neuritis. This effect may be related to dosage and duration of treatment. This effect is generally reversible when use of the drug is discontinued promptly. However, irreversible blindness has been observed. Since this drug may have adverse effects on vision, physical examination should include ophthalmoscopy, finger perimetry and testing of color discrimination. In patients with visual defects such as cataracts, recurrent inflammatory conditions of the eye, optic neuritis, and diabetic retinopathy, the evaluation of changes in visual acuity is more difficult, and care should be taken to make sure that variations in vision are not due to the underlying disease conditions. In these patients, consideration should be given to relationship between benefits expected and possible visual deterioration since evaluation of visual changes is difficult. All patients receiving Liskobutol should be instructed to report any vision changes or disturbances. Testing of visual acuity should be performed before beginning Liskobutol and periodically during drug administration. Monthly visual acuity testing should be done for patients receiving more than 15 mg per kilogram per day.

Liver toxicities including fatalities have been observed. Baseline and periodic assessment of hepatic function should be performed.

Patients with decreased renal function should have the dosage reduced as determined by serum levels of Liskobutol, since the main path of excretion of this drug is by the kidneys. Baseline and periodic assessment of renal function should be performed.

Baseline and periodic assessment of hematopoietic function should be performed.

Liskobutol may elevate serum uric acid levels and should be used cautiously in patients with preexisting gout. Patients should be monitored for hyperuricemia.

There are limited data on the use of Liskobutol in elderly patients. One study of 101 patients, 65 years and older, on multiple drug antituberculosis regimens included 94 patients on Liskobutol therapy. No differences in safety or tolerability were reported in these patients compared with that reported in adults in general. Other observed clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Dialysis

Liskobutol is slightly dialyzable (5% to 20%). The dose should be administered post-dialysis.

Other Comments

Liskobutol or streptomycin are used as part of a combination therapy with isoniazid, rifampin, and pyrazinamide. If susceptibility to isoniazid and rifampin is shown, Liskobutol may be discontinued.

More about Liskobutol

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 1 Review - Add your own review/rating

Consumer resources

• Liskobutol
• Liskobutol (Advanced Reading)

• Other brands: Liskobutol

Professional resources

• Liskobutol Hydrochloride (AHFS Monograph)
• More (2) »

Related treatment guides

• Tuberculosis, Active
• Mycobacterium avium-intracellulare, Prophylaxis
• Mycobacterium avium-intracellulare, Treatment

What other drugs will affect Liskobutol?

Do not take antacids that contain aluminum within several hours of taking a dose of Liskobutol. Aluminum will decrease the amount of Liskobutol that is absorbed by the body. If you need an antacid, ask your doctor or pharmacist to recommend one that is aluminum free.

Drugs other than those listed here may also interact with Liskobutol. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including vitamins, minerals, and herbal products.

Liskobutol interactions

Aluminum Hydroxide: May decrease the serum concentration of Liskobutol. Management: Avoid concurrent administration of Liskobutol and aluminum hydroxide. If coadministration cannot be avoided administer Liskobutol first and then wait at least 4 hours before administering aluminum hydroxide-containing products. Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification

References

1. DailyMed. "ETHAMBUTOL HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. FDA/SPL Indexing Data. "8G167061QZ: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
3. MeSH. "Antitubercular Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Liskobutol are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Liskobutol. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology